KPI data tables
GSK operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.
| Period | US | Europe | International |
|---|---|---|---|
| Q3 2026 | 55 | 103 | 37 |
| Q2 2026 | 65 | 30 | 97 |
| Q1 2026 | 18 | 43 | 4 |
| Q4 2025 | 71 | 106 | 21 |
| Q3 2025 | 140 | 75 | 36 |
| Q2 2025 | 35 | 18 | 13 |
| Q1 2025 | 55 | 19 | 4 |
Source: GSK plc quarterly results announcements, Vaccines turnover tables, RSV / Arexvy row by region (amounts in millions of pounds). Q3 2026 (28 Oct 2026, Form 6-K) https://www.sec.gov/Archives/edgar/data/1131399/000165495426009181/a6993a.htm US 55 / Europe 103 / International 37, total 195. Q2 2026 https://www.gsk.com/media/jayh41pz/q2-2026-results-announcement.pdf US 65 / Europe 30 / International 97, total 192. Q1 2026 https://www.gsk.com/media/hpgfxwxv/q1-2026-results-announcement.pdf 18 / 43 / 4, total 65. Q4 2025 https://www.gsk.com/media/g0lnid23/fy-2025-results-announcement.pdf 71 / 106 / 21, total 198. Q3 2025 https://www.gsk.com/media/snycbnpn/q3-2025-results-announcement.pdf 140 / 75 / 36, total 251. Q2 2025 https://www.gsk.com/media/zhfdbsly/q2-2025-results-announcement.pdf 35 / 18 / 13, total 66. Q1 2025 https://www.gsk.com/media/lwfjtr0d/q1-2025-results-announcement.pdf 55 / 19 / 4, total 78. FY 2023 1,238 / FY 2024 590 / FY 2025 593 from the 2025 Annual Report on Form 20-F three-year Vaccines turnover table https://www.gsk.com/media/3rxjw5di/investor-information-2025.pdf.
| Period | Dovato | Cabenuva | Apretude | Other HIV |
|---|---|---|---|---|
| Q3 2026 | 754 | 478 | 143 | 741 |
| Q2 2026 | 749 | 453 | 140 | 736 |
| Q1 2026 | 666 | 368 | 120 | 670 |
| Q4 2025 | 758 | 410 | 129 | 852 |
| Q3 2025 | 695 | 357 | 120 | 772 |
| Q2 2025 | 655 | 341 | 101 | 783 |
| Q1 2025 | 570 | 294 | 89 | 761 |
Source: GSK plc quarterly results announcements, Specialty Medicines turnover tables, HIV product rows (amounts in millions of pounds). Q3 2026 (28 Oct 2026, Form 6-K) https://www.sec.gov/Archives/edgar/data/1131399/000165495426009181/a6993a.htm Dovato 754 / Cabenuva 478 / Apretude 143 / HIV total 2,116. Q2 2026 https://www.gsk.com/media/jayh41pz/q2-2026-results-announcement.pdf Dovato 749 / Cabenuva 453 / Apretude 140 / HIV total 2,078. Q1 2026 https://www.gsk.com/media/hpgfxwxv/q1-2026-results-announcement.pdf 666 / 368 / 120 / 1,824. Q4 2025 https://www.gsk.com/media/g0lnid23/fy-2025-results-announcement.pdf 758 / 410 / 129 / 2,149. Q3 2025 https://www.gsk.com/media/snycbnpn/q3-2025-results-announcement.pdf 695 / 357 / 120 / 1,944. Q2 2025 https://www.gsk.com/media/zhfdbsly/q2-2025-results-announcement.pdf 655 / 341 / 101 / 1,880. Q1 2025 https://www.gsk.com/media/lwfjtr0d/q1-2025-results-announcement.pdf 570 / 294 / 89 / 1,714. Other HIV is HIV total minus the three named products. FY 2025 Dovato 2,678 / Cabenuva 1,402 / Apretude 439 / HIV 7,687 in the 2025 Annual Report on Form 20-F https://www.gsk.com/media/3rxjw5di/investor-information-2025.pdf.
| Period | US | Europe | International |
|---|---|---|---|
| Q3 2026 | 290 | 289 | 201 |
| Q2 2026 | 245 | 434 | 209 |
| Q1 2026 | 389 | 461 | 176 |
| Q4 2025 | 331 | 370 | 307 |
| Q3 2025 | 256 | 297 | 277 |
| Q2 2025 | 241 | 359 | 253 |
| Q1 2025 | 372 | 291 | 204 |
Source: GSK plc quarterly results announcements, Vaccines turnover tables, Shingles / Shingrix row by region (amounts in millions of pounds). Q3 2026 (28 Oct 2026, Form 6-K) https://www.sec.gov/Archives/edgar/data/1131399/000165495426009181/a6993a.htm US 290 / Europe 289 / International 201, total 780. Q2 2026 https://www.gsk.com/media/jayh41pz/q2-2026-results-announcement.pdf US 245 / Europe 434 / International 209, total 888. Q1 2026 https://www.gsk.com/media/hpgfxwxv/q1-2026-results-announcement.pdf 389 / 461 / 176, total 1,026. Q4 2025 https://www.gsk.com/media/g0lnid23/fy-2025-results-announcement.pdf 331 / 370 / 307, total 1,008. Q3 2025 https://www.gsk.com/media/snycbnpn/q3-2025-results-announcement.pdf 256 / 297 / 277, total 830. Q2 2025 https://www.gsk.com/media/zhfdbsly/q2-2025-results-announcement.pdf 241 / 359 / 253, total 853. Q1 2025 https://www.gsk.com/media/lwfjtr0d/q1-2025-results-announcement.pdf 372 / 291 / 204, total 867. FY 2025 US 1,200 / Europe 1,317 / International 1,041 in the 2025 Annual Report on Form 20-F investor information https://www.gsk.com/media/3rxjw5di/investor-information-2025.pdf.
| Period | Specialty Medicines | Vaccines | General Medicines |
|---|---|---|---|
| Q3 2026 | 3,877 | 2,583 | 2,427 |
| Q2 2026 | 3,782 | 2,284 | 2,343 |
| Q1 2026 | 3,226 | 2,149 | 2,254 |
| Q4 2025 | 3,805 | 2,293 | 2,520 |
| Q3 2025 | 3,409 | 2,678 | 2,460 |
| Q2 2025 | 3,327 | 2,091 | 2,568 |
| Q1 2025 | 2,933 | 2,095 | 2,488 |
Source: GSK plc quarterly results announcements, turnover by product group table (amounts in millions of pounds). Q3 2026 (28 Oct 2026, Form 6-K) https://www.sec.gov/Archives/edgar/data/1131399/000165495426009181/a6993a.htm Q3 2026 Specialty 3,877 / Vaccines 2,583 / General Medicines 2,427. Q2 2026 (28 Jul 2026) https://www.gsk.com/media/jayh41pz/q2-2026-results-announcement.pdf Q2 2026 Specialty 3,782 / Vaccines 2,284 / General Medicines 2,343. Q1 2026 https://www.gsk.com/media/hpgfxwxv/q1-2026-results-announcement.pdf 3,226 / 2,149 / 2,254. FY 2025 / Q4 2025 https://www.gsk.com/media/g0lnid23/fy-2025-results-announcement.pdf Q4 3,805 / 2,293 / 2,520. Q3 2025 https://www.gsk.com/media/snycbnpn/q3-2025-results-announcement.pdf 3,409 / 2,678 / 2,460. Q2 2025 https://www.gsk.com/media/zhfdbsly/q2-2025-results-announcement.pdf 3,327 / 2,091 / 2,568. Q1 2025 https://www.gsk.com/media/lwfjtr0d/q1-2025-results-announcement.pdf 2,933 / 2,095 / 2,488. Three-year annual totals in the 2025 Annual Report on Form 20-F investor information https://www.gsk.com/media/0t2lqb2w/2025-annual-report-on-form-20-f.pdf and https://www.gsk.com/media/3rxjw5di/investor-information-2025.pdf (Specialty 13,474 / Vaccines 9,157 / General Medicines 10,036 in 2025).
| Period | Shingrix | Meningitis | Arexvy | Influenza | Established / other paediatric and adult |
|---|---|---|---|---|---|
| Q3 2026 | 780 | 599 | 195 | 177 | 832 |
| Q2 2026 | 888 | 462 | 192 | 11 | 731 |
| Q1 2026 | 1,026 | 335 | 65 | 10 | 713 |
| Q4 2025 | 1,008 | 313 | 198 | 80 | 694 |
| Q3 2025 | 830 | 541 | 251 | 216 | 840 |
| Q2 2025 | 853 | 379 | 66 | 6 | 787 |
| Q1 2025 | 867 | 350 | 78 | 1 | 799 |
Source: GSK plc quarterly results announcements, Vaccines turnover tables (amounts in millions of pounds). Q3 2026 (28 Oct 2026, Form 6-K) https://www.sec.gov/Archives/edgar/data/1131399/000165495426009181/a6993a.htm Shingles 780 / Meningitis 599 / RSV 195 / Influenza 177 / Other Paediatric and Adult Vaccines 832, Vaccines 2,583. Q2 2026 https://www.gsk.com/media/jayh41pz/q2-2026-results-announcement.pdf Shingles 888 / Meningitis 462 / RSV 192 / Influenza 11 / Other Paediatric and Adult Vaccines 731, Vaccines 2,284. Q1 2026 https://www.gsk.com/media/hpgfxwxv/q1-2026-results-announcement.pdf 1,026 / 335 / 65 / 10 / 713, Vaccines 2,149. Q4 2025 https://www.gsk.com/media/g0lnid23/fy-2025-results-announcement.pdf 1,008 / 313 / 198 / 80 / Established 694, Vaccines 2,293. Q3 2025 https://www.gsk.com/media/snycbnpn/q3-2025-results-announcement.pdf 830 / 541 / 251 / 216 / 840, Vaccines 2,678. Q2 2025 https://www.gsk.com/media/zhfdbsly/q2-2025-results-announcement.pdf 853 / 379 / 66 / 6 / 787, Vaccines 2,091. Q1 2025 https://www.gsk.com/media/lwfjtr0d/q1-2025-results-announcement.pdf 867 / 350 / 78 / 1 / 799, Vaccines 2,095. FY 2025 mix in the 2025 Annual Report on Form 20-F https://www.gsk.com/media/3rxjw5di/investor-information-2025.pdf Shingles 3,558 / Meningitis 1,583 / RSV 593 / Influenza 303 / Established 3,120, Vaccines 9,157.